Among 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. CytomX Therapeutics had 4 analyst reports since November 2, 2015 according to SRatingsIntel. The rating was initiated by Oppenheimer with “Outperform” on Monday, November 2. The rating was initiated by Jefferies with “Buy” on Monday, November 2. The firm has “Outperform” rating given on Monday, November 2 by Cowen & Co. Oppenheimer downgraded CytomX Therapeutics, Inc. (NASDAQ:CTMX) on Tuesday, January 3 to “Perform” rating. See CytomX Therapeutics, Inc. (NASDAQ:CTMX) latest ratings:
The stock of Paychex, Inc. (NASDAQ:PAYX) reached all time high today, Dec, 16 and still has $73.96 target or 6.00% above today’s $69.77 share price. This indicates more upside for the $25.07B company. This technical setup was reported by Barchart.com. If the $73.96 PT is reached, the company will be worth $1.50 billion more. The stock increased 2.11% or $1.44 during the last trading session, reaching $69.77. About 3.55M shares traded or 75.54% up from the average. Paychex, Inc. (NASDAQ:PAYX) has risen 11.22% since December 16, 2016 and is uptrending. It has underperformed by 5.48% the S&P500.
Investors sentiment decreased to 1.02 in Q2 2017. Its down 0.01, from 1.03 in 2017Q1. It dropped, as 45 investors sold Paychex, Inc. shares while 279 reduced holdings. 68 funds opened positions while 265 raised stakes. 237.67 million shares or 1.25% less from 240.68 million shares in 2017Q1 were reported. Manning Napier reported 78,767 shares. Private Tru Na invested 0.08% in Paychex, Inc. (NASDAQ:PAYX). Texas Permanent School Fund holds 89,836 shares. Schmidt P J Mgmt Inc invested in 4,645 shares. Capital Guardian has 15,000 shares. Callahan Advisors Limited Liability Company accumulated 131,550 shares or 1.63% of the stock. 9,754 were accumulated by Thompson Siegel & Walmsley Ltd Liability. Duncker Streett & Co owns 6,812 shares for 0.12% of their portfolio. Cidel Asset Mgmt Inc stated it has 3,675 shares or 0.01% of all its holdings. Moreover, Washington Trust has 0.1% invested in Paychex, Inc. (NASDAQ:PAYX). Fin Counselors reported 0.26% stake. Mitchell Mcleod Pugh And Williams Incorporated owns 0.28% invested in Paychex, Inc. (NASDAQ:PAYX) for 6,452 shares. Penobscot has invested 0.08% in Paychex, Inc. (NASDAQ:PAYX). Reliance Tru Com Of Delaware stated it has 14,995 shares. Ranger Mngmt Limited Partnership holds 2.08% or 8,010 shares.
Among 18 analysts covering Paychex (NASDAQ:PAYX), 2 have Buy rating, 2 Sell and 14 Hold. Therefore 11% are positive. Paychex had 37 analyst reports since August 14, 2015 according to SRatingsIntel. Robert W. Baird maintained the stock with “Hold” rating in Monday, September 11 report. Citigroup maintained the shares of PAYX in report on Wednesday, October 4 with “Sell” rating. The firm has “Hold” rating given on Thursday, August 17 by Stifel Nicolaus. The stock of Paychex, Inc. (NASDAQ:PAYX) has “Hold” rating given on Tuesday, October 3 by Robert W. Baird. The rating was maintained by RBC Capital Markets on Wednesday, June 28 with “Sell”. The company was upgraded on Wednesday, January 11 by Bernstein. The stock of Paychex, Inc. (NASDAQ:PAYX) has “Buy” rating given on Friday, December 16 by Goldman Sachs. The stock of Paychex, Inc. (NASDAQ:PAYX) has “Equal Weight” rating given on Tuesday, December 20 by Barclays Capital. Citigroup upgraded Paychex, Inc. (NASDAQ:PAYX) on Monday, December 4 to “Hold” rating. On Monday, November 20 the stock rating was maintained by RBC Capital Markets with “Sell”.
Since September 25, 2017, it had 0 insider buys, and 5 insider sales for $5.53 million activity. Zaucha Laurie L. had sold 17,354 shares worth $1.11M on Monday, October 9. $1.88 million worth of Paychex, Inc. (NASDAQ:PAYX) was sold by MUCCI MARTIN. Vossler Jennifer R. sold $703,546 worth of Paychex, Inc. (NASDAQ:PAYX) on Friday, October 6.
Paychex, Inc. provides payroll, human resource , retirement, and insurance services for small to medium-sized businesses in the United States and Germany. The company has market cap of $25.07 billion. The firm offers payroll processing services that include payroll tax administration services; employee payment services; and regulatory compliance services, such as new-hire reporting and garnishment processing. It has a 30.6 P/E ratio. It also provides HR outsourcing services, such as Paychex HR solutions comprising payroll, employer compliance, HR and employee benefits administration, risk management outsourcing, and the on-site availability of a professionally trained HR representative; and retirement services administration, including plan implementation, ongoing compliance with government regulations, employee and employer reporting, participant and employer online access, electronic funds transfer, and other administrative services.
Analysts await Paychex, Inc. (NASDAQ:PAYX) to report earnings on December, 20. They expect $0.59 earnings per share, up 5.36% or $0.03 from last year’s $0.56 per share. PAYX’s profit will be $212.00M for 29.56 P/E if the $0.59 EPS becomes a reality. After $0.62 actual earnings per share reported by Paychex, Inc. for the previous quarter, Wall Street now forecasts -4.84% negative EPS growth.
The stock decreased 0.42% or $0.09 during the last trading session, reaching $21.57. About 1.32M shares traded or 246.76% up from the average. CytomX Therapeutics, Inc. (NASDAQ:CTMX) has risen 50.10% since December 16, 2016 and is uptrending. It has outperformed by 33.40% the S&P500.